Elevian, an emerging biotech company, has signed a research and development collaboration with United States-based Insilico Medicine to produce oral medications targeting the GDF11 pathway and associated targets, it was reported yesterday.

The partnership will utilise Insilico's generative adversarial networks and reinforcement learning AI technologies to discover novel small molecules that target the GDF11 pathway, which has been demonstrated to play an important role in aging and age-related disease.

Agenus is to use Selexis' technology to produce therapeutic proteins. In order to succeed in this endeavour, both firms will use state-of-the-art techniques in AI-enabled drug discovery. Based on biological and structural target data from Elevian, Insilico will identify small molecules that produce the intended biological actions utilising deep learning technology.